Nutritional supplements company Natural Alternatives International Inc (NASDAQ:NAII) reported on Wednesday the receipt of a Notice of Allowance for its instant release beta-alanine patent application entitled "Methods And Compositions For Increasing The Anaerobic Working Capacity In Tissues" from the US Patent and Trademark Office.
The US Patent and Trademark Office's new accepted application is part of the company's global patent estate covering its CarnoSyn instant release beta-alanine product.
According to the company, the new allowed claims are directed to methods of delaying muscle fatigue through supplementation with instant release beta-alanine in times and amounts to increase muscle carnosine levels beyond that obtainable through diet alone.
In addition, the claimed methods allow for a loading phase and a maintenance phase of supplementation and allows for further loading after achieving and maintaining a desired level of muscle carnosine, concluded the company.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA